Combining the latest compound screening technologies with the flexibility you need to meet your goals
In our decade plus of operation, we have brought our specialized expertise in DNA-encoded library (DEL) screening, machine learning and artificial intelligence (AI) to hundreds of drug discovery projects, all of which presented with different goals and challenges. Drawing on this rich experience and our culture of collaboration, we’re ready to guide you on how best to apply our technologies and solutions to achieve your project goals.
When your aim is to build a pipeline around a focused biological hypothesis, X-Chem integrates DEL, medicinal chemistry, computational sciences, and a long track record of success to jumpstart your program. Our DEL screening services are a great way to get high-quality equity with multiple series. Further accelerate your program by front-loading the project with the full data sets, and unlock the full value of a 250-billion compound screen with our expert computational chemistry approaches to build pharmacophores and SAR maps of your target. Then, utilize HITMiner, our DEL-AI solution, to expand the chemical space of your program and immediately use off-the shelf compounds while our synthetic chemists create a full swath of multiple series compounds refined through X-Chem’s expert computational and medicinal chemistry.
X-Chem’s integrated drug discovery teams then partner with you to move rapidly through the DMTA process all the way to the clinic. Throughout the process, you will interact directly with scientists and managers who are dedicated to bringing your collaboration to a successful outcome, providing access to data and tools. We are your scientific partner.
If you already have a large or growing pipeline or you want unfettered access to DEL screening and data, DELenable may be the right solution. X-Chem can get you operating an internal DEL capability with minimal investment. Our DELenable clients are secure in knowing that they are screening the world’s most advanced DELs with support from the leading DEL informatics platform.
For companies who already operate DELs, our products can improve and supplement your existing DEL platform. Our ReadiDEL libraries enable our clients to immediately bolster their DEL collection with our advanced DEL designs. Additionally, our ReadiBLOX provide DEL-specific reagents to facilitate synthesis of high-quality libraries. After screening, our clients can generate predictive models using their proprietary data by accessing our ArtemisAI platform.
When it comes to the business of biopharmaceutical research, X-Chem is now more flexible than ever, ensuring that we will find the right collaboration model for any partner.